Under the acquisition, Curoverse will apply its artificial intelligence services to Veritas Genetics’ genomic platform. Veritas Genetics plans to use the AI capabilities to create the first automated interpretation platform for human genomes.
The Veritas Genetics platform is projected to exceed 10 petabytes of genomic data this year — and genomic data is “notoriously non-standardized in the ways it is produced and aggregated,” according to a Veritas Genetics statement.
“This will only be possible by deploying AI and machine learning at scale, which requires data that is produced, stored and managed in a standardized way,” explains Mirza Cifric, co-founder and CEO of Veritas Genetics. “Curoverse excels at this capability.”
The financial details of the transaction were not disclosed. Upon completion of the acquisition, Curoverse will operate as a wholly owned subsidiary of Veritas Genetics.
More articles on health IT:
Former CMS Administrator Dr. Don Berwick joins Virta Health board
Judy Faulkner, Joe Biden reportedly clash over patient access to EHRs
Paper records are here to stay: 4 questions with Illinois Pain Institute’s Dr. John Prunskis
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.